StemCell Therapy

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation.

Continue reading here:
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)

See the original post here:
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Gross profit expected to surge by 32.6%

Read the original:
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales

DALLAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- From January 20-23, 2025, North Texas took center stage as a global hub for innovation during Advanced Therapies Week (ATW) 2025. This signature event showcased the intersection of cutting-edge science, transformative healthcare solutions, and dynamic regional collaboration. Hosted in Dallas, ATW 2025 convened industry leaders, researchers, and visionaries to explore the future of cell and gene therapy. From breakthroughs in gene editing to scalable advancements in cell therapy manufacturing, the event underscored the immense potential of advanced therapies to transform medicine and improve lives worldwide.

Read the original:
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences

Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years

Visit link:
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors

2024 revenue

Go here to see the original:
GUERBET : 2024 revenue.

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company’s plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.

See more here:
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

VALNEVA

Here is the original post:
Shareholding declaration Valneva SE - January 2025

Monthly information relative to the total number of voting rights and shares composing the share capital

See the original post:
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Raised approximately $2.118 million in gross proceeds since the beginning of 2025 Raised approximately $2.118 million in gross proceeds since the beginning of 2025

Original post:
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Clermont-Ferrand (France), 6 February 2025 (18:30 CET). CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme.

More:
CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET.

Read more:
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense® 365 CGM system.

Continue reading here:
Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company’s Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.

Link:
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has signed an advisory agreement with Mr. Matthew Azrieli. Mr. Azrieli is a current shareholder of PharmAla Biotech.

Read the original here:
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026

Original post:
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure (ACLF) pipeline, with several clinical data readouts by end of 2025.

Originally posted here:
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

The rest is here:
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds

View original post here:
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Execution of a share buyback agreement for up to €2 billion

Follow this link:
Press Release: Execution of a share buyback agreement for up to €2 billion